After a one-two punch of disappointing news for Gilead out of China, where as we reported yesterday a trial of remdesivir in Covid-19 patients with mild or moderate symptoms was suspended as no eligible patients could be recruited according to an update on ClinicalTrials.gov, which in turn followed a trial of the drug in severely ill Covid-19 patients which was also terminated for similar reasons, it felt like one or more hedge funds would seek to manipulate public sentiment – and the market – and get out of an underwater position.
They did just that at 430pm today when the low profile Statnews published a report by Adam Feuerstein, best known for doing the bidding of one or more hedge fund clients, according to which a “Chicago hospital treating severe Covid-19 patients with Gilead Sciences’ antiviral medicine remdesivir in a closely watched clinical trial is seeing rapid recoveries in fever and respiratory symptoms, with nearly all patients discharged in less than a week, STAT has learned.”
“Learned” from whom? A hedge fund or two who were long GILD and needed a fake news catalyst to get out? Because last time we checked, double blind, secret drug trials are, er… secret.
